Business
Immutep : Systemic immune activation with eftilagimod alfa associated with statistically significant increased overall survival in late-stage cancer patients
Immutep : Systemic immune activation with eftilagimod alfa associated with statistically significant increased overall survival in late-stage cancer
About this update from Immutep Ltd
[{"type":"text","content":"\n Systemic immune activation with eftilagimod alfa associated with statistically significant increased overall survival in late-stage cancer patients\n \n May 28, 2026\n \n Print / PDF\n \n SYDNEY, AUSTRALIA, May 28, 2026 - Immutep Limited (ASX: IMM; NASDAQ: IMMP) (\"Immutep\" or \"the Company\"), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, today announced results from a systematic evaluation of 5 clinical trials of eftilagimod alfa (\"efti\") an antigen-presenting cell (APC) activator in combination with standard-of-care (SOC) therapies in late-stage cancer patients.\n \n \n In these trials, treatment with 30 mg subcutaneous (SC) efti plus SOC resulted in a significant increase in circulating absolute lymphocyte count (ALC), a blood-based measure of immune activity, compared to SOC alone where this effect was not seen. More importantly, increased ALC was significantly associated with improved clinical outcomes in the E+SOC group. A clinically meaningful and significant median overall survival (OS) improvement (median +7.7 months; p=0.00171) was seen in ALC responders compared to ALC non-responders in the efti + SOC group (figure on the left). No corresponding association between ALC response and OS was observed in the SOC alone group (figure on the right).\n \n \n The analysis included 5922 patients across five independent clinical studies (TACTI-mel, TACTI-002, TACTI-003, AIPAC, AIPAC-003) spanning four cancer indications (NSCLC, HNSCC, MBC, melanoma), correlating the pharmacological effects of efti in combination with SOC treatments with clinical efficacy.\n \n \n Overall survival of late-stage cancer patients treated with SOC + efti (left) and SOC alone (right), ALC responders vs ALC non-responders.\n \n \n \n Effects were observed across the different tumor types and were independent of the combination partner i.e., chemotherapy or immunotherapy such as PD-1 antagonists.\n \n \n \"These findings link the immune-activating effect of efti measured in patients´ blood with meaningful and significant survival improvements observed in previous clinical trials. Importantly, this highlights a key connection between efti´s mechanism of action and clinical efficacy,\" said Frederic Triebel, Chief Scientific Officer of Immutep.\n \n \n In addition, treatment with efti plus SOC was associated with ...